Lyell Immunopharma moved -5.6% this morning session, trading between a high of $3.229 and a low of $2.94 per share. Yesterday the stock finished at $3.19 per share, compared to an average analyst target price of $7.25.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. The small-cap biotechnology: pharmaceutical preparations company is based in the United States. Lyell Immunopharma has trailing twelve months earnings per share (EPS) of -0.81, which at today's prices amounts to a price to earnings (P/E) ratio of -3.7.
Based on its expected future earnings growth, the company has a price to earnings growth (PEG) ratio of 0.31. Usually a PEG ratio between 0 and 1 indicates a potentially undervalued company.
Snapshot of Lyell Immunopharma's Operating Margins:
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2021-12-31 | 10,650 | 225,426 | -2016.68 | 26.2 |
| 2020-12-31 | 7,756 | 219,693 | -2732.56 | 82.41 |
| 2019-12-31 | 657 | 102,746 | -15538.7 | n/a |
Averaging out to -6762.6% over the last 3 years, Lyell Immunopharma's operating margins also have a high coefficient of variability, which stands at 112.5%. On the other hand, we note that the firm's margins are growing at a 49.4% compounded average yearly rate.
